Experience that moves the industry forward.

Dr. Samarasimhareddy Mamidi leads SMS Peptides as Chief Executive Officer. A peptide chemist by training, Dr. Mamidi is responsible for the company’s scientific direction, partnerships and growth.

Dr. Mamidi earned a PhD from Bangalore University, specialising in the synthesis of peptides and peptidomimetics, and completed postdoctoral research at the Hebrew University of Jerusalem. That work spanned multi-phosphorylated peptides, click cyclisation of peptoids and photolabile protecting groups for complex glycan synthesis.

Before joining SMS Peptides, Dr. Mamidi was Head of Peptide Chemistry at RG Discovery in Lund, Sweden, a Scandinavian drug discovery company developing small-molecule and peptide therapeutics for pharmaceutical and biotech partners.

At SMS Peptides, Dr. Mamidi brings this international drug discovery experience together with the manufacturing strength of SMS Pharmaceuticals.

Mr. Ramesh Babu is the Founder Chairman of SMS Pharmaceuticals Limited. Across four decades he has built the company on a single idea: that essential medicines should be within the economic reach of millions of patients.

That same conviction led to SMS Peptides. Seeing peptide therapeutics move from a specialist niche to the centre of metabolic medicine, he championed the decision to build a dedicated peptide company rather than treat peptides as a side activity, and he committed the group’s capital and manufacturing base behind it.

His influence reaches well beyond SMS. He has served on the boards of industry bodies such as Chemexcil and advised the Government of Andhra Pradesh on the pharmaceutical sector, giving him a rare view of both the upstream and downstream sides of the industry.

As a board director of SMS Peptides, he guides our long-term direction and keeps the focus on medicines that reach patients at scale.

Mr. Vamsi Krishna graduated from BITS Pilani, Dubai, and holds a master’s degree in engineering management from Missouri University of Science and Technology in the United States. He began in supply chain at OHM Laboratories, learning how international markets buy and qualify pharmaceutical materials.

He joined the SMS group early in his career and now leads operations at SMS Pharmaceuticals, shaping them for the needs of a new generation of medicines.

He was one of the driving forces behind the creation of SMS Peptides, and his support is what turns our chemistry into supply. Through him, our programmes draw on the group’s GMP plants, quality systems and supply chain, including the dedicated peptide plant coming up at Unit 7, Visakhapatnam.

That backing is why a partner can move from first binder to multi-kilogram GMP manufacturing without leaving the same team.